Literature DB >> 19471912

Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.

Heli Halava1, Arja Helin-Salmivaara, Jouni Junnila, Risto Huupponen.   

Abstract

PURPOSE: The aim of the study was to investigate preferential initiation with the two most frequently used statins, simvastatin and atorvastatin, by patient characteristics over time.
METHODS: Statin initiators without a statin prescription during the 365 days preceding the initiation from 1 January 1998 through 31 December 2004 were captured from the nation-wide Prescription Register in Finland. Associations of demographic factors and morbidities with atorvastatin versus simvastatin at initiation of statin treatment were analysed by a logistic regression model adjusted for significant covariates separately for each year.
RESULTS: Of all new statin users in 1998, atorvastatin was chosen for 18% and simvastatin for 39%. In 2004, the corresponding figures were 32 and 38%. Atorvastatin was more likely than simvastatin to be initiated in younger age groups than in persons older than 74 years (reference group). Initiation with atorvastatin was less likely for people with than without coronary artery disease; adjusted odds ratios ranged from 0.62 to 0.73 over the years 1998-2003.
CONCLUSION: Channelling of atorvastatin over simvastatin toward the younger and healthier population was found during the first 4 years after its launch in Finland. Channelling may lead to confounding by indication, which must be taken into account when designing pharmacoepidemiology studies on statins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19471912     DOI: 10.1007/s00228-009-0664-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Are patients more satisfied when they receive a prescription? The effect of patient expectations in general practice.

Authors:  W Himmel; E Lippert-Urbanke; M M Kochen
Journal:  Scand J Prim Health Care       Date:  1997-09       Impact factor: 2.581

2.  Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Authors:  Zheng Zhou; Elham Rahme; Michal Abrahamowicz; Jack V Tu; Mark J Eisenberg; Karin Humphries; Peter C Austin; Louise Pilote
Journal:  CMAJ       Date:  2005-04-26       Impact factor: 8.262

3.  The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey.

Authors:  N Britten; O Ukoumunne
Journal:  BMJ       Date:  1997-12-06

4.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Authors:  P Jones; S Kafonek; I Laurora; D Hunninghake
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

5.  Patient expectations on lipid-lowering drugs.

Authors:  Per Lytsy; Ragnar Westerling
Journal:  Patient Educ Couns       Date:  2007-04-11

6.  The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.

Authors:  Fausto G Patino; Jeroan Allison; Jason Olivieri; Amy Mudano; Lucia Juarez; Sharina Person; Ted R Mikuls; Larry Moreland; Stacey H Kovac; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2003-06-15

7.  Factors associated with celecoxib and rofecoxib utilization.

Authors:  Nigel S B Rawson; Parivash Nourjah; Stella C Grosser; David J Graham
Journal:  Ann Pharmacother       Date:  2005-03-08       Impact factor: 3.154

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.

Authors:  Kathleen Bennett; Mary Teeling; John Feely
Journal:  Eur J Clin Pharmacol       Date:  2003-08-27       Impact factor: 2.953

10.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

View more
  5 in total

1.  Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.

Authors:  Helle Wallach-Kildemoes; Ebba Holme Hansen
Journal:  Eur J Clin Pharmacol       Date:  2015-07-31       Impact factor: 2.953

2.  Statin Therapy and Risk of Acute Memory Impairment.

Authors:  Brian L Strom; Rita Schinnar; Jason Karlawish; Sean Hennessy; Valerie Teal; Warren B Bilker
Journal:  JAMA Intern Med       Date:  2015-08       Impact factor: 21.873

3.  Sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events.

Authors:  Arja Helin-Salmivaara; Piia Lavikainen; Emma Aarnio; Risto Huupponen; Maarit Jaana Korhonen
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

4.  A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.

Authors:  David M Kern; Setareh A Williams; Ozgur Tunceli; Catrin Wessman; Siting Zhou; Ned Pethick; Hanaa Elhefni; Frank Trudo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-07-18

5.  Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.

Authors:  Anke Neumann; Géric Maura; Alain Weill; Philippe Ricordeau; François Alla; Hubert Allemand
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-12-02       Impact factor: 2.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.